Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), announces the completion and positive results of ALA-1000 ...
Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) for 12 monthsRAHWAY, ...
A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...
A sick dog, desperate owner, and a bunch of chatbots made for a great story. The actual science was much messier.
Merck's animal health unit got approval for a drug to treat and control certain ticks in dogs from the Food and Drug Administration. Merck said Wednesday its Bravecto Quantum is now approved to treat ...
Officials with the FDA have approved a label expansion for fluralaner for extended-release injectable suspension (Bravecto ...
Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.
Merck’s (MRK) animal health unit announced that the U.S. FDA approved a label expansion for its once-yearly parasiticide treatment Bravecto Quantum to treat two additional tick species in dogs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results